Pacira Pharmaceuticals, Inc. (PCRX)

[surf1944]

6:30AM Pacira Pharma announces new data support the benefits of EXPAREL for postsurgical analgesia following aesthetic plastic surgery procedures (PCRX) 29.30 : Co announced results from EXCLAIM, its Phase 4 prospective, observational study to assess the use of EXPAREL (bupivacaine liposome injectable suspension) for postsurgical analgesia in patients undergoing four common plastic surgery procedures. Patients who received EXPAREL following abdominoplasty, breast augmentation, breast reduction or a combination abdominoplasty/breast procedure reported low pain scores, high satisfaction with pain control and minimal opioid use. Key findings demonstrated that patients treated with EXPAREL reported:

Low pain scores (mean score of =4.0 on pain intensity scale of 0-10)
Minimal opioid use for rescue pain relief (mean of <3 tablets taken daily vs historically expected 10 tablets per day in a typical postsurgical pain management paradigm)
High satisfaction with pain management (all patients reported =3.0 on a 0-4 scale)
Excellent overall benefit of analgesia (OBAS) achieved with EXPAREL (mean score of =5 out of a possible 28 points)